Hepatitis b core protein modulators

A compound represented by:

• wherein
• Y is SO2;
• RY is selected from the group consisting of H, methyl, ethyl, propyl, propenyl, butyl, phenyl and benzyl;
• RZ is selected from the group consisting of H, methyl, ethyl, propyl, phenyl and benzyl;
• Rc is selected from the group consisting of H, C1-6alkyl and C2-6alkenyl;
• X2 is selected from the group consisting of S(O)w (wherein w is 0, 1, or 2), 0, —C(O)— and NR′;
• R58 and R59 are each independently selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, NR′R″, —C(O)—C1-6alkyl, —C(O)—C1-6alkoxy, phenyl, heteroaryl, C3-6cycloalkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR′R″ (where w is 0, 1 or 2), and —NR′—S(O)w—C1-6alkyl (where w is 0, 1 or 2);
• or form a phenyl, heterocyclic or heteroaryl ring (optionally substituted by one, two, or three substituents selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR′R″) and fused to the ring to which they are attached;
• R′ is selected, independently for each occurrence, from H, methyl, ethyl, cyclopropyl, cyclobutyl, and propyl;
• R″ is selected, independently for each occurrence, from H, methyl, ethyl, propyl (optionally substituted by hydroxyl), butyl (optionally substituted by hydroxyl), —C(O)-methyl and —C(O)-ethyl, or R′ and R″ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle optionally substituted by one or more substituents selected from the group consisting of halogen, NH2, —C(O)—O—C1-6alkyl, —C(O)—C1-6alkyl, carboxy and C1-6alkyl;
• R″, for each occurrence, is selected from the group consisting of H, halogen, and C1-6alkyl (optionally substituted with one, two, or three halogens);
• each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR′R″;
• wherein for each occurrence, C1-6alkyl, C2-6alkenyl or C2-6alkynyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C3-6cycloalkyl, C2-4alkenyl, C2-4alkynyl, C1-3alkoxy, NR′R″, —NR′—S(O)w—C1-2alkyl (where w is 0, 1 or 2), NR′—C(O)—C1-3alkyl, NR′—C(O)—O—C1-3alkyl, —NR′—S(O)w, and S(O)w—NR′R″;
• C1-6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C1-3alkyl, NR′R″, —NR′—S(O)w—C1-2alkyl (where w is 0, 1 or 2), and S(O)w—NR′R″ (where w is 0, 1 or 2);
• C1-6alkylene may be optionally substituted by a substituent selected from the group consisting of C3-6cycloalkyl, hydroxyl, cyano, and halogen;
• or a pharmaceutically acceptable salt thereof.